Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Change in Accured Expenses (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed Change in Accured Expenses for 7 consecutive years, with -$6.0 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 300750.0% to -$6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, up 128.52% year-over-year, with the annual reading at $2.4 million for FY2025, 128.52% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$6.0 million at Strata Critical Medical, down from $7.5 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $7.5 million in Q3 2025, with the low at -$10.2 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $1.0 million, with a median of $1.9 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses soared 6692.36% in 2021, then tumbled 300750.0% in 2025.
  • Over 5 years, Change in Accured Expenses stood at $1.9 million in 2021, then surged by 193.4% to $5.6 million in 2022, then dropped by 12.08% to $5.0 million in 2023, then crashed by 100.04% to -$2000.0 in 2024, then crashed by 300750.0% to -$6.0 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$6.0 million, $7.5 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.